RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

CNBC — Apr 16, 17:44 PM

Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

Read full article at CNBC →

Hims & Hers Rallies on Peptides

How RFK Jr. Sent Hims & Hers Stock Higher Barrons — Apr 16, 12:46 PM
Hims & Hers Health Stock Rallies on Regulatory Pivot. It’s Not About GLP-1s This Time. Barrons — Apr 16, 12:46 PM
Hims rises as FDA considers broader peptides access; analysts see long-term win - Reuters Reuters — Apr 16, 15:35 PM